Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma

NCT01970527 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01970527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01970527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2014
Completion date
June 21, 2019
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent melanoma, stage iv skin melanoma